Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus MICONAZOLE 3 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus MICONAZOLE 3 COMBINATION PACK.
KERYDIN vs MICONAZOLE 3 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and fungal cell death.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
Intravaginal: 1 applicatorful (100 mg) at bedtime for 3 consecutive nights.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Terminal elimination half-life is 20-25 hours (intravaginal administration). This long half-life supports a 3-day dosing regimen, maintaining therapeutic concentrations.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Renal: approximately 10-20% as unchanged drug; fecal: >50% as metabolites; biliary: minor route. The majority is eliminated via feces as metabolites, reflecting hepatic metabolism and biliary excretion.
Category C
Category A/B
Antifungal
Antifungal